SCHEMBL6416522

SCHEMBL6416522

O=[C]CCC1CCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7349456 0.94 CYP2D6 (0.46)
SCHEMBL7294980 0.80 HRH3 (0.42)
SCHEMBL13552291 0.78
SCHEMBL398826 0.78
SCHEMBL13961615 0.78 CYP2D6 (0.43)
SCHEMBL349705 0.77
SCHEMBL6781145 0.75
SCHEMBL197630 0.75
SCHEMBL20633400 0.74 CYP2D6 (0.40)
SCHEMBL5539780 0.72 CXCR4 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030083230-A1 Reversal of multidrug resistance in human colon carcinoma cells AMERICAN CYANAMID COMPANY 2003-05-01 US claimed
US-20020169111-A1 Reversal of multidrug resistance in human colon carcinoma cells AMERICAN CYANAMID COMANY (US) 2002-11-14 US claimed
US-20020156015-A1 Reversal of multidrug resistance in human colon carcinoma cells AMERICAN CYANAMID COMPANY 2002-10-24 US claimed
US-6372775-B1 ANTICANCER AGENT AMERICAN CYANAMID COMPANY 2002-04-16 US claimed
US-5856556-A Azetidinone derivatives, a process for their preparation and their use as intermediates in the preparation of carbapenem antibiotics SANKYO COMPANY, LIMITED (JP) 1999-01-05 US claimed
US-6878737-B2 Reversal of multidrug resistance in human colon carcinoma cells WYETH HOLDINGS CORPORATION (US) 2005-04-12 US disclosed
US-20030083230-A1 Reversal of multidrug resistance in human colon carcinoma cells AMERICAN CYANAMID COMPANY 2003-05-01 US disclosed
US-6537964-B1 The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs. WYETH HOLDINGS CORPORATION 2003-03-25 US disclosed
US-20020169111-A1 Reversal of multidrug resistance in human colon carcinoma cells AMERICAN CYANAMID COMANY (US) 2002-11-14 US disclosed
US-20020156015-A1 Reversal of multidrug resistance in human colon carcinoma cells AMERICAN CYANAMID COMPANY 2002-10-24 US disclosed
US-6372775-B1 ANTICANCER AGENT AMERICAN CYANAMID COMPANY 2002-04-16 US disclosed
US-5856556-A Azetidinone derivatives, a process for their preparation and their use as intermediates in the preparation of carbapenem antibiotics SANKYO COMPANY, LIMITED (JP) 1999-01-05 US disclosed
US-5436254-A Vaopressin antagonists OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) 1995-07-25 US disclosed
EP-0382185-B1 Carbostyril derivatives OTSUKA PHARMA CO LTD (JP) 1994-06-15 EP disclosed
US-5225402-A Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-07-06 US disclosed
US-5102997-A Antibiotics SANKYO COMPANY LIMITED (JP) 1992-04-07 US disclosed
EP-0382185-A2 Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-08-16 EP disclosed
EP-0102239-B1 AZETIDINONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS INTERMEDIATES IN THE PREPARATION OF CARBAPENEM ANTIBIOTICS SANKYO COMPANY LIMITED (JP) 1987-10-14 EP disclosed
EP-0160391-A1 Carbapenem derivatives and compositions containing them SANKYO COMPANY LIMITED (JP) 1985-11-06 EP disclosed
EP-0102239-A1 Azetidinone derivatives, a process for their preparation and their use as intermediates in the preparation of carbapenem antibiotics SANKYO COMPANY LIMITED (JP) 1984-03-07 EP disclosed